Xtant Medical Holdings Inc 2026年季度报告

FORM 10-Q XTANT MEDICAL HOLDINGS, INC. TABLE OF CONTENTS CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS PART I.FINANCIAL INFORMATIONITEM 1.FINANCIAL STATEMENTS ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFOPERATIONS18ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK23ITEM 4.CONTROLS AND PROCEDURES23 This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of theSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe As used in this report, unless the context indicates another meaning, the terms “we,” “us,” “our,” “Xtant,” “Xtant Medical,”and the “Company” mean Xtant Medical Holdings, Inc. and its wholly owned subsidiaries, all of which are consolidated on Xtant’s We own various unregistered trademarks and service marks, including our corporate logo. Solely for convenience, thetrademarks and trade names in this report are referred to without the ® and ™ symbols, but such references should not be construedas any indicator that the owner of such trademarks and trade names will not assert, to the fullest extent under applicable law, their We include our website address throughout this report for reference only. The information contained on or connected to ourwebsite is not incorporated by reference into this report. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS The statements contained in this Quarterly Report on Form 10-Q that are not purely historical are forward-looking statementswithin the meaning of the Private Securities Litigation Reform Act of 1995. Our forward-looking statements include, but are notlimited to, statements regarding our expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, anystatements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlyingassumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” ●our ability to maintain and increase revenue and improve our gross margins, our operating expenses as a percentage of ●our ability to execute our strategic priorities and become operationally self-sustaining by controlling our supply chainand becoming less reliant on production and manufacturing of our products outside of our control, which we believe will ●our ability and success in implementing key growth and process improvement initiatives designed to increase ourproduction capacity, revenue, and scale and risks associated with such growth and process improvement initiatives; ●risks associated with strategic transactions, including our recently announced exclusive distribution agreement withDilon Technologies, Inc. (“Dilon”), the recent sale of certain assets relating to our Coflex and CoFix products and our ●our ability to sell successfully the HEMOBLAST® Bellows product that we distribute on an exclusive basis and theeffect of this arrangement, including our hiring of approximately 20 additional sales personnel in connection therewith ●the effect of global economic and geopolitical conditions, including economic uncertainty and a possible futurerecession, tariffs, inflation, rising interest rates, and supply chain disruptions on our business, operating results andfinancial position, which, among other effects, could result in delayed product launches, lost revenue, higher costs, ●our dependence on and ability to retain and recruit qualified sales personnel, independent sales agents and distributorsand motivate and incentivize them to engage with customers and sell our products, including in particular, ourdependence on the sales personnel we recently hired in connection with our exclusive distribution agreement with Dilon ●the ability of our sales personnel, independent sales agents and distributors to achieve expected results, includingleveraging our additional sales personnel to sell other Xtant products, and the potential adverse effects on our business ●our ability to innovate, develop, introduce, market and license new products and technologies and the success of suchnew products and technologies, including the HEMOBLAST® Bellows product that recently began distributing on anexclusive basis; our recently launched nanOss Strata™, an advanced synthetic bone graft designed to closely resemblenatural bone; CollagenX™, a bovine collagen particulate product for surgical wound closure; OsteoFactor Pro™, an ●the effect of our private label and original equipment manufacturer (“OEM”) business on our business and operatingresults and risks associated therewith, including fluctuations in our operating results and decreased profit margins, and ●our ability to retain and expand our agreements with group purchasing organizations (“GPOs”) and integrated deliverynetworks (“IDNs”) and sell products